NCT01243151View on ClinicalTrials.gov

Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
HypercholesterolemiaDyslipidemia
Interventions
BIOLOGICAL

PF-04950615 (RN316)

Infusion every week

BIOLOGICAL

PF-04950615 (RN316)

Infusion every week

BIOLOGICAL

PF-04950615 (RN316)

Infusion every week

BIOLOGICAL

PF-04950615 (RN316)

Infusion every week

BIOLOGICAL

PF-04950615 (RN316)

Infusion every week

Trial Locations (9)

33126

SeaView Research, Inc., Miami

33134

SeaView Research, Inc., Miami

55114

Prism Research, Saint Paul

66211

Vince and Associates Clinical Research, Overland Park

66212

Vince and Associates Clinical Research, Overland Park

78209

Healthcare Discoveries, LLC dba ICON Development Solutions, San Antonio

90232

California Clinical Trials Medical Group, Culver City

91206

Glendale Adventist Medical Center, Glendale

96813

Covance Clinical Research Unit, Inc., Honolulu

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY